Friday, May 16, 2025
5/16/2025
Targeting Surfactant Protein A to Prevent Retinopathy of Prematurity - PROJECT SUMMARY Retinopathy of prematurity (ROP) is a potentially blinding vaso-proliferative disease frequently seen in prematurely born infants with lifelong consequences for both the infant and society. The c-type lectin, Surfactant Protein A (SP-A), is an immunomodulatory protein, found to be deficient in prematurely born infants. Lack of SP-A is associated with lung disease of prematurity and a temporal association with pulmonary vascular growth factors has been previously reported. We previously discovered that SP-A is expressed in the Müller retina and plays an important role in neovascular disease (NV) with a pro-angiogenic phenotype. Our preliminary data now shows SP-A promotes early retinal vascular development, and conversely, lack of SP-A is seen in response to hyperoxia in rodent models. SP-A has a positive association with expression of retinal vascular endothelial growth factor (VEGF), cytoskeleton proteins and associated chaperones necessary for both cytoskeleton and VEGF folding. Our results suggest that deficiency of SP-A leads to reduced vascular growth in endothelial cells both in the rodent retina and in vitro impacting retinal angiogenesis. Conversely, in the second stage, SP-A acts in a proangiogenic fashion to drive NV. Given that current anti-VEGF therapies for ROP may result in delayed re-appearance of NV and may also depress systemic VEGF levels with consequences for the growing preterm infant, there is a critical need to develop safe and targeted therapies for ROP and most importantly- to prevent it. We hypothesize that the SP-A protein and associated pathways represent novel therapeutic targets to rescue early hyperoxia and prematurity related vascular arrest. It is imperative to understand the mechanisms for these complex cell-intrinsic properties. In this proposal we will examine cytoskeleton, chaperone and S-A receptor molecules using transgenic strains with targeted deletion of SP-A and Myo18A receptor in Müller and endothelial cells. We will examine the association between SP-A and the chaperone aCrystallinB which drive post-translational modification of cytoskeleton and vascular growth factors. The goals of this proposal are to characterize the SP-A/chaperone/VEGF axis, to confirm Myo18A as the SP-A receptor and study the impact of SP-A on endothelial cell cytoskeleton and endothelial cell function. Finally, we will test the therapeutic potential of targeting SP-A protein in early disease in a rodent ROP model. These goals have clear
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).